National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Insulin Degludec (Tresiba®)

Treatment of diabetes mellitus

Rapid Review

Commenced Completed Outcome
17/12/2012 04/01/2013  Full Pharmacoeconomic Assessment Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
04/11/2014  04/05/2015 Reimbursement Not Recommended at the submitted price


December 2015

The HSE has approved reimbursement following confidential price negotiations.


In pharmacoeconomic evaluation, ‘technology’ is used to mean a drug or other treatment that is being assessed.

Time Horizon

Period of time over which costs and outcomes are measured in economic evaluation.

Tofacitinib (Xeljanz®) for Ulcerative Colitis

Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor).


NCPE Assessment Process Complete
Rapid review commissioned 16/07/2018
Rapid review completed 18/09/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

Tolvaptan (Jinarc®)

Jinarc®) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.

NCPE Assessment Process Complete
Rapid review received 04/01/2016
Rapid review completed 12/01/2016
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 27/01/2017
Full pharmacoeconomic assessment re-commissioned by HSE 14/08/2017
Pre-submission consultation with applicant 18/09/2017
Submission received from applicant 06/02/2018
Preliminary review sent to applicant 03/04/2018
NCPE assessment re-commenced 14/05/2018
Preliminary review 2 sent to applicant 03/07/2018
NCPE assessment recommenced
Factual accuracy sent to applicant 27/08/2018
NCPE assessment recommenced 06/09/2018
NCPE assessment completed 13/09/2018
NCPE assessment outcome The NCPE recommends that tolvaptan not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.


Transition Probability

The probability that the health of a patient changes from one health state to another health state within a given period